Glucofree (Metformin Hydrochloride)

Glucofree (Metformin Hydrochloride) is indicated for the treatment of type 2 diabetes mellitus in adults, typically as part of a broader therapeutic regimen.

• Improves glycemic control when combined with diet and exercise.
• May be used as monotherapy in patients newly diagnosed with type 2 diabetes.
• Can be added to insulin therapy to reduce insulin dose requirements.
• May be combined with other oral antidiabetic agents such as sulfonylureas or DPP‑4 inhibitors.
• Used in clinical practice to help achieve target HbA1c levels.

The safety profile of Glucofree reflects the typical adverse event spectrum of metformin, with most patients experiencing mild to moderate symptoms that often resolve without intervention. These effects are generally dose‑related and may lessen over time as the body adjusts to therapy.

Common

• Nausea or upset stomach.
• Diarrhea, sometimes loose stools.
• Metallic taste in the mouth.
• Decreased appetite or mild abdominal discomfort.
• Headache or dizziness.
• Unexplained weight loss or mild fatigue.
• Mild constipation.
• Elevated liver enzymes (rare).

Serious

• Lactic acidosis, a rare but potentially life‑threatening condition.
• Severe skin reactions such as Stevens‑Johnson syndrome.
• Acute renal failure in patients with pre‑existing kidney disease.

When prescribing Glucofree, clinicians consider several precautionary factors to minimize risk and ensure appropriate patient selection.

• Assess renal function before initiation and periodically during therapy.
• Use with caution in patients with hepatic impairment or a history of alcohol abuse.
• Monitor for signs of vitamin B12 deficiency with long‑term use.
• Adjust dose or discontinue if gastrointestinal intolerance is severe.
• Avoid use in patients with known hypersensitivity to metformin or other biguanides.
• Consider pregnancy status; metformin is generally avoided unless benefits outweigh risks.

Glucofree may interact with other medicines, affecting its efficacy or increasing the risk of adverse events. Awareness of these interactions helps guide safe co‑administration.

Avoid

• Iodinated contrast agents – discontinue Glucofree before and after imaging to reduce lactic acidosis risk.
• Cimetidine – may increase metformin plasma concentrations.
• Certain antivirals (e.g., didanosine) – can potentiate metformin toxicity.
• Beta‑blockers – may mask symptoms of hypoglycemia.

Use with caution

• Diuretics – monitor renal function as combined effect may impair clearance.
• ACE inhibitors or ARBs – watch for changes in kidney function and electrolytes.
• Statins – monitor for rare cases of myopathy when combined.